Amarin reported $300.57M in Current Liabilities for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Liabilities Change
DBV Technologies DBVT:US 26.03M 5.37M
Abbvie ABBV:US $ 32521M 2673M
Aerie Pharmaceuticals AERI:US $ 115.29M 9.7M
Alnylam Pharmaceuticals ALNY:US $ 605.96M 89.75M
Amarin AMRN:US $ 300.57M 70.11M
AstraZeneca AZN:LN 22740M 146M
Biocryst Pharmaceuticals BCRX:US $ 81.02M 22.7M
Epizyme EPZM:US $ 38.97M 6.23M
Esperion Therapeutics ESPR:US $ 79.08M 5.73M
GlaxoSmithKline GSK:LN 24278M 608M
Halozyme Therapeutics HALO:US $ 111.69M 5.46M
Heron Therapeutics HRTX:US $ 93M 21.94M
Intercept Pharmaceuticals ICPT:US $ 151.04M 15.78M
JAZZ PHA JAZZ:US $ 737.41M 71.89M
Nektar Therapeutics NKTR:US $ 85.2M 54.77M
Novartis NOVN:VX SF 29807M 401M
Teva Pharmaceutical Industries TEVA:US $ 11613M 586M